These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65. A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas' disease. Araújo MS; Martins-Filho OA; Pereira ME; Brener Z J Antimicrob Chemother; 2000 Jun; 45(6):819-24. PubMed ID: 10837436 [TBL] [Abstract][Full Text] [Related]
66. Soluble platelet selectin (sP-selectin) and soluble vascular cell adhesion molecule-1 (sVCAM-1) decrease during therapy with benznidazole in children with indeterminate form of Chagas' disease. Laucella SA; Segura EL; Riarte A; Sosa ES Clin Exp Immunol; 1999 Dec; 118(3):423-7. PubMed ID: 10594562 [TBL] [Abstract][Full Text] [Related]
67. Long term evaluation of etiological treatment of chagas disease with benznidazole. Cancado JR Rev Inst Med Trop Sao Paulo; 2002; 44(1):29-37. PubMed ID: 11896410 [TBL] [Abstract][Full Text] [Related]
68. Therapeutic efficacy of allopurinol in patients with chronic Chagas' disease. Gallerano RH; Marr JJ; Sosa RR Am J Trop Med Hyg; 1990 Aug; 43(2):159-66. PubMed ID: 2117857 [TBL] [Abstract][Full Text] [Related]
69. The role of benznidazole with cyanocobalamin and ascorbic acid in treating the chronic phase of Chagas disease. Ghobadifar MA; Kalani N; Gitiforouz M; Mosallanejad Z Rev Soc Bras Med Trop; 2014; 47(5):669. PubMed ID: 25467275 [No Abstract] [Full Text] [Related]
70. Assessment of cytogenetic damage in chagasic children treated with benznidazole. Gorla NB; Ledesma OS; Barbieri GP; Larripa IB Mutat Res; 1988 Oct; 206(2):217-20. PubMed ID: 3140001 [TBL] [Abstract][Full Text] [Related]
71. Treatment with Fenofibrate plus a low dose of Benznidazole attenuates cardiac dysfunction in experimental Chagas disease. Cevey ÁC; Mirkin GA; Donato M; Rada MJ; Penas FN; Gelpi RJ; Goren NB Int J Parasitol Drugs Drug Resist; 2017 Dec; 7(3):378-387. PubMed ID: 29040909 [TBL] [Abstract][Full Text] [Related]
72. Treatment and seroconversion in a cohort of children suffering from recent chronic Chagas infection in Yoro, Honduras. Escribà JM; Ponce E; Romero Ade D; Viñas PA; Marchiol A; Bassets G; Palma PP; Lima MA; Zúniga C; Ponce C Mem Inst Oswaldo Cruz; 2009 Nov; 104(7):986-91. PubMed ID: 20027465 [TBL] [Abstract][Full Text] [Related]
73. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Viotti R; Vigliano C; Lococo B; Bertocchi G; Petti M; Alvarez MG; Postan M; Armenti A Ann Intern Med; 2006 May; 144(10):724-34. PubMed ID: 16702588 [TBL] [Abstract][Full Text] [Related]
74. Population pharmacokinetics and biodistribution of benznidazole in mice. Perin L; Pinto L; Balthazar Nardotto GH; da Silva Fonseca K; Oliveira Paiva B; Fernanda Rodrigues Bastos Mendes T; Molina I; Correa-Oliveira R; Melo de Abreu Vieira P; Martins Carneiro C J Antimicrob Chemother; 2020 Aug; 75(8):2213-2221. PubMed ID: 32356873 [TBL] [Abstract][Full Text] [Related]
75. Usefulness of PCR for monitoring benznidazole response in patients with chronic Chagas' disease: a prospective study in a non-disease-endemic country. Murcia L; Carrilero B; Muñoz MJ; Iborra MA; Segovia M J Antimicrob Chemother; 2010 Aug; 65(8):1759-64. PubMed ID: 20542903 [TBL] [Abstract][Full Text] [Related]
76. Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease. Olivera MJ; Cucunubá ZM; Valencia-Hernández CA; Herazo R; Agreda-Rudenko D; Flórez C; Duque S; Nicholls RS PLoS One; 2017; 12(9):e0185033. PubMed ID: 28949997 [TBL] [Abstract][Full Text] [Related]
77. Longitudinal follow up of serological response in children treated for Chagas disease. Moscatelli G; Moroni S; García Bournissen F; González N; Ballering G; Schijman A; Corral R; Bisio M; Freilij H; Altcheh J PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007668. PubMed ID: 31465522 [TBL] [Abstract][Full Text] [Related]
78. Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease. Rial MS; Scalise ML; Arrúa EC; Esteva MI; Salomon CJ; Fichera LE PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006119. PubMed ID: 29267280 [TBL] [Abstract][Full Text] [Related]
79. [Protective effect of benznidazole against parasite reactivation in patients chronically infected with Trypanosoma cruzi and treated with corticoids for associated diseases]. Rassi A; Amato Neto V; de Siqueira AF; Ferriolli Filho F; Amato VS; Rassi Júnior A Rev Soc Bras Med Trop; 1999; 32(5):475-82. PubMed ID: 10881079 [TBL] [Abstract][Full Text] [Related]
80. Development of UV/HPLC methods for quantitative analysis of benznidazole in human plasma and urine for application in pediatric clinical studies. Marsón ME; Dana DD; Altcheh J; García-Bournissen F; Mastrantonio G J Clin Lab Anal; 2013 Sep; 27(5):384-90. PubMed ID: 24038224 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]